Portfolio company
NewLimit
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This biotechnology company develops epigenetic reprogramming medicines to restore cellular function and treat age-related diseases for patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Altos Labs
This biotechnology company develops cellular rejuvenation therapies to restore cell health and reverse diseases for patients with chronic illnesses and age-related disabilities.
clock.bio
This biotechnology company develops regenerative therapies for patients with age-related diseases by using gene-editing technology to decode cellular rejuvenation programs in human stem cells.
Neotis
This company develops immunotherapies targeting senescent cells to treat age-related and fibrotic diseases for patients with chronic conditions.
Shift Bioscience
This biotechnology company develops cellular rejuvenation therapeutics and an AI-driven discovery platform for pharmaceutical researchers to treat age-related diseases.
Life Biosciences
This biotechnology company develops cellular rejuvenation therapies using epigenetic restoration to treat age-related diseases, such as optic neuropathies, for patients with chronic conditions.
ImmuneAGE
This company develops a drug discovery platform for creating therapies that rejuvenate the immune system by targeting hematopoietic stem cells in the bone marrow.
BioAge Labs
This company develops therapeutic drugs targeting the biology of human aging to treat patients with metabolic and cardiovascular diseases.
Regcell
This biotechnology company develops regulatory T-cell therapies using an epigenetic reprogramming platform to treat patients with autoimmune diseases and inflammatory conditions.
